End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.3 MXN | +3.16% | +8.23% | +15.11% |
Sales 2023 | 16.47B 961M 76.88B | Sales 2024 * | 18.2B 1.06B 84.99B | Capitalization | 15.15B 884M 70.74B |
---|---|---|---|---|---|
Net income 2023 | 1.03B 60.16M 4.81B | Net income 2024 * | 2.18B 127M 10.16B | EV / Sales 2023 | 1.07 x |
Net Debt 2023 | 4.52B 264M 21.1B | Net Debt 2024 * | 1.97B 115M 9.18B | EV / Sales 2024 * | 0.94 x |
P/E ratio 2023 |
13.1
x | P/E ratio 2024 * |
7.41
x | Employees | 1,783 |
Yield 2023 |
1.38% | Yield 2024 * |
1.43% | Free-Float | 69.81% |
Latest transcript on Genomma Lab Internacional, S.A.B. de C.V.
1 day | +3.16% | ||
1 week | +8.23% | ||
Current month | +3.30% | ||
1 month | +3.30% | ||
3 months | +12.34% | ||
6 months | +22.93% | ||
Current year | +15.11% |
Managers | Title | Age | Since |
---|---|---|---|
Marco Sparvieri
CEO | Chief Executive Officer | - | - |
Founder | - | 29/10/96 | |
Director of Finance/CFO | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Burkhard Wittek
BRD | Director/Board Member | 70 | 17/04/18 |
Founder | - | 29/10/96 | |
Director/Board Member | - | 31/12/97 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 15 M€ | -1.62% | - | |
0.04% | 31 M€ | +3.50% | - | |
0.01% | 4 M€ | -4.41% | - | |
0.01% | 117 M€ | +1.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 16.3 | +3.16% | 4,739,936 |
25/04/24 | 15.8 | +8.29% | 6,136,163 |
24/04/24 | 14.59 | -3.25% | 4,193,193 |
23/04/24 | 15.08 | -1.76% | 2,265,864 |
22/04/24 | 15.35 | +1.93% | 3,368,367 |
End-of-day quote Mexican S.E., April 25, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.11% | 882M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- LAB B Stock